» Authors » Mark E Metzger

Mark E Metzger

Explore the profile of Mark E Metzger including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 876
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Suryawanshi G, Kim S, Guan X, Bonifacino A, Metzger M, et al.
Heliyon . 2023 Oct; 9(9):e19435. PMID: 37810095
Selective T-cell depletion prior to cell or organ transplantation is considered a preconditioning regimen to induce tolerance and immunosuppression. An immunotoxin consisting of a recombinant anti-CD3 antibody conjugated with diphtheria...
2.
Stringaris K, Hoyt R, Davidson-Moncada J, Pantin J, Tisdale J, Uchida N, et al.
Blood Adv . 2020 Dec; 4(24):6148-6156. PMID: 33351110
Intrabone (IB) injection of umbilical cord blood has been proposed as a potential mechanism to improve transplant engraftment and prevent graft failure. However, conventional IB techniques produce low retention of...
3.
de Ravin S, Brault J, Meis R, Li L, Theobald N, Bonifacino A, et al.
Blood Adv . 2020 Dec; 4(23):5976-5987. PMID: 33284949
Granulocytes from patients with chronic granulomatous disease (CGD) have dysfunctional phagocyte reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase that fails to generate sufficient antimicrobial reactive oxidative species. CGD patients with...
4.
Uchida N, Hsieh M, Raines L, Haro-Mora J, Demirci S, Bonifacino A, et al.
Nat Commun . 2019 Oct; 10(1):4479. PMID: 31578323
Hematopoietic stem cell (HSC) gene therapy is being evaluated for hemoglobin disorders including sickle cell disease (SCD). Therapeutic globin vectors have demanding requirements including high-efficiency transduction at the HSC level...
5.
Uchida N, Fujita A, Hsieh M, Bonifacino A, Krouse A, Metzger M, et al.
Hum Gene Ther Clin Dev . 2017 Apr; 28(3):136-144. PMID: 28447889
Steady state bone marrow (BM) is the preferred hematopoietic stem cell (HSC) source for gene therapy in sickle cell disease (SCD) due to the recognized risk of vaso-occlusive crisis during...
6.
Uchida N, Weitzel R, Shvygin A, Skala L, Raines L, Bonifacino A, et al.
Mol Ther Methods Clin Dev . 2016 Sep; 3:16059. PMID: 27652288
Reduced intensity conditioning (RIC) is desirable for hematopoietic stem cell (HSC) gene therapy applications. However, low gene marking was previously observed in gene therapy trials, suggesting that RIC might be...
7.
Donahue R, Srinivasula S, Uchida N, Kim I, St Claire A, Duralde G, et al.
Blood . 2015 Oct; 126(24):2632-41. PMID: 26492933
Ionizing irradiation is used routinely to induce myeloablation and immunosuppression. However, it has not been possible to evaluate the extent of ablation without invasive biopsy. For lymphoid recovery, peripheral blood...
8.
Barese C, Felizardo T, Sellers S, Keyvanfar K, Di Stasi A, Metzger M, et al.
Stem Cells . 2014 Oct; 33(1):91-100. PMID: 25330775
The high risk of insertional oncogenesis reported in clinical trials using integrating retroviral vectors to genetically modify hematopoietic stem and progenitor cells (HSPCs) requires the development of safety strategies to...
9.
Hong S, Winkler T, Wu C, Guo V, Pittaluga S, Nicolae A, et al.
Cell Rep . 2014 May; 7(4):1298-1309. PMID: 24835994
Induced pluripotent stem cell (iPSC)-based cell therapies have great potential for regenerative medicine but are also potentially associated with tumorigenic risks. Current rodent models are not optimal predictors of efficiency...
10.
Kim S, Kim N, Presson A, Metzger M, Bonifacino A, Sehl M, et al.
Cell Stem Cell . 2014 Apr; 14(4):473-85. PMID: 24702996
In mice, clonal tracking of hematopoietic stem cells (HSCs) has revealed variations in repopulation characteristics. However, it is unclear whether similar properties apply in primates. Here, we examined this issue...